Roche (company)
Projected $270 Billion Orphan Drug Market by 2028: A Comprehensive Analysis of Leading Players J&J, Vertex, and Roche
Orphan drugs, rare diseases, J&J, Vertex, Roche, market growth, 2028, Evaluate
Roche’s Strategic Shift Affects 20% of New Molecules, as Cancer Candidates are Reassessed
Roche, pipeline, rethink, new molecules, cancer candidates, discard pile, strategic shift, pharmaceutical industry, drug development, oncology research
Roche Streamlines Portfolio, Prioritizes High-Impact Projects After Pipeline Reduction
Roche, pharmaceuticals, pipeline, portfolio optimization, high-impact projects, strategic decision, drug development
Roche’s Alecensa Gains FDA Approval for Postsurgical Early Lung Cancer Treatment
Roche, Alecensa, FDA approval, Postsurgical treatment, Early lung cancer
Alecensa: FDA-Approved First ALK Inhibitor for Adjuvant Treatment in Early-Stage ALK-Positive NSCLC
Alecensa, ALK Inhibitor, Adjuvant Treatment, Early-Stage ALK-Positive NSCLC, FDA Approval, Genentech, Roche Group, ALINA Study, 76% Reduction in Disease Recurrence or Death, NCCN Guidelines
Roche’s Ocrevus Demonstrates Near-Complete Reduction of Relapse and Lesions in Multiple Sclerosis
Ocrevus, Roche, Multiple Sclerosis (MS), Relapse reduction, Lesion reduction, Clinical and MRI measures
Adaptimmune Terminates $3 Billion Collaboration with Roche’s Genentech for Off-the-Shelf T Cell Therapies
Adaptimmune, Roche, Genentech, Off-the-shelf T cell therapies, $3 billion biobucks pact, Collaboration termination
Roche’s Phase III Trial Success with IL-6 Blocker Enspryng Tempered by Modest Outcomes
Roche, IL-6 blocker, Enspryng (satralizumab), Phase III trial, Generalized Myasthenia Gravis (gMG), Disappointment, Expectations
Lonza Acquires Roche’s Massive Biologics Production Facility in Vacaville, California for $1.2 Billion
Lonza, Roche, Genentech, Biologics Manufacturing Site, Vacaville/ California, $1.2 Billion Deal, Large-Scale Commercial Mammalian Products, Expansion Plans ($561 Million), Capacity Utilization, Contract Development and Manufacturing Organizations (CDMOs), Global Biologics Market Growth
Roche and Alnylam’s Hypertension Hopeful Zilebesiran Shows Promising Results in Combination Therapy Trial
Roche, Alnylam, Zilebesiran, Hypertension, Combination Therapy, Phase 2 Trial, Blood Pressure Control, AngioTensinogen (AGT), RNA Interference (RNAi) Therapeutic, Significant Reductions in Systolic Blood Pressure, Encouraging Safety Profile